At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 69 enrolled
Drug / intervention
PF-00299804drug
Likely dose
PF-00299804 45 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CLINICAL PHASE 2 MULTICENTER TRIAL OF PF-00299804 IN PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
In Brief
A Phase 2 clinical trial evaluating PF-00299804 for Head and Neck Neoplasms. Completed, enrolled 69 participants across 10 sites.
Detailed Summary
This study will investigate the safety and efficacy of oral PF-00299804 in patients who have not yet undergone any other drug treatment for recurrent and/ or metastatic head and neck squamous cell cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Neoplasms
CountriesCanada
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2008
Enrollment StartNov 2008
Primary CompletionMay 2010
Study CompletionApr 2012
TodayJul 2026
First PostedOct 8, 2008
Enrollment StartNov 4, 2008
Primary CompletionMay 5, 2010
Study CompletionApr 18, 2012
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 17.7 years ago
Interventions
PF-00299804drug
45 mg by continuous oral dosing